Immunosuppression with cyclosporine versus tacrolimus shows distinctive nephrotoxicity profiles within renal compartments

Research output: Contribution to journalResearch articleContributedpeer-review

Contributors

  • Hasan Demirci - , Charité – Universitätsmedizin Berlin (Author)
  • Suncica Popovic - , Charité – Universitätsmedizin Berlin (Author)
  • Carsten Dittmayer - , Charité – Universitätsmedizin Berlin (Author)
  • Duygu Elif Yilmaz - , Charité – Universitätsmedizin Berlin (Author)
  • Ismail Amr El-Shimy - , Charité – Universitätsmedizin Berlin (Author)
  • Michael Mülleder - , Charité – Universitätsmedizin Berlin (Author)
  • Christian Hinze - , Hannover Medical School (MHH) (Author)
  • Mingzhen Su - , Charité – Universitätsmedizin Berlin (Author)
  • Philipp Mertins - , Charité – Universitätsmedizin Berlin, Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Marieluise Kirchner - , Charité – Universitätsmedizin Berlin, Max Delbrück Center for Molecular Medicine (MDC) (Author)
  • Bilgin Osmanodja - , Charité – Universitätsmedizin Berlin (Author)
  • Alexander Paliege - , Department of Internal Medicine III, University Hospital Carl Gustav Carus Dresden (Author)
  • Klemens Budde - , Charité – Universitätsmedizin Berlin (Author)
  • Kerstin Amann - , University Hospital at the Friedrich-Alexander University Erlangen-Nürnberg (Author)
  • Pontus B Persson - , Charité – Universitätsmedizin Berlin (Author)
  • Kerim Mutig - , Sechenov First Moscow State Medical University (Author)
  • Sebastian Bachmann - , Charité – Universitätsmedizin Berlin (Author)

Abstract

AIM: Calcineurin inhibitors (CNIs) are the backbone for immunosuppression after solid organ transplantation. Although successful in preventing kidney transplant rejection, their nephrotoxic side effects contribute to allograft injury. Renal parenchymal lesions occur for cyclosporine A (CsA) as well as for the currently favored tacrolimus (Tac). We aimed to study whether chronic CsA and Tac exposures, before reaching irreversible nephrotoxic damage, affect renal compartments differentially and whether related pathogenic mechanisms can be identified.

METHODS: CsA and Tac were administered chronically in wild type Wistar rats using osmotic minipumps over 4 weeks. Functional parameters were controlled. Electron microscopy, confocal, and 3D-structured illumination microscopy were used for histopathology. Clinical translatability was tested in human renal biopsies. Standard biochemical, RNA-seq, and proteomic technologies were applied to identify implicated molecular pathways.

RESULTS: Both drugs caused significant albeit differential damage in vasculature and nephron. The glomerular filtration barrier was more affected by Tac than by CsA, showing prominent deteriorations in endothelium and podocytes along with impaired VEGF/VEGFR2 signaling and podocyte-specific gene expression. By contrast, proximal tubule epithelia were more severely affected by CsA than by Tac, revealing lysosomal dysfunction, enhanced apoptosis, impaired proteostasis and oxidative stress. Lesion characteristics were confirmed in human renal biopsies.

CONCLUSION: We conclude that pathogenetic alterations in the renal compartments are specific for either treatment. Considering translation to the clinical setting, CNI choice should reflect individual risk factors for renal vasculature and tubular epithelia. As a step in this direction, we share protein signatures identified from multiomics with potential pathognomonic relevance.

Details

Original languageEnglish
Article numbere14190
JournalActa Physiologica Scandinavica
Volume240
Issue number8
Publication statusPublished - Aug 2024
Peer-reviewedYes

External IDs

Scopus 85196220641

Keywords

Keywords

  • Animals, Cyclosporine/adverse effects, Humans, Immunosuppressive Agents/adverse effects, Kidney Transplantation, Kidney/drug effects, Male, Rats, Rats, Wistar, Tacrolimus/pharmacology